# A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT05381935** · PHASE1 · WITHDRAWN · sponsor: **Elpiscience Biopharma, Ltd.**

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ES014
- **DRUG:** ES014

## Key facts

- **NCT ID:** NCT05381935
- **Lead sponsor:** Elpiscience Biopharma, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-04-21
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor's clinical development strategy adjustment
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05381935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05381935, "A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05381935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*